Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot

被引:0
|
作者
Iwama, Eimei [1 ]
Fujimura, Taku [1 ]
Kusakari, Yoshiyuki [1 ]
Haga, Takahiro [1 ]
Aiba, Setsuya [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源
CASE REPORTS IN DERMATOLOGY | 2015年 / 7卷 / 03期
关键词
Malignant melanoma in situ; BRAF(V600E) mutation; PD-L1;
D O I
10.1159/000441601
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Melanoma is an aggressive skin cancer that originates from melanocytes, and about one half of melanoma cases possess a BRAF mutation. Together with PD-L1 expression, the BRAF(V600E) mutation is one of the optimal therapeutic targets for the treatment of melanoma. In this report, we describe a case of multifocal melanoma in situ on the foot, which carried the p.V600E mutation in the BRAF gene. Interestingly, the spotted melanoma lesion is demarcated by normal skin, and in all spotted pigmented lesions, there were no signs of dermal invasion of melanoma cells or spontaneous regression. Our case presented atypical clinical features, which might correlate with the local mutations of BRAF gene and the immunological expression of PD-L1. (C) 2015 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:322 / 327
页数:6
相关论文
共 50 条
  • [1] BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
    Del Bufalo, Francesca
    Ceglie, Giulia
    Cacchione, Antonella
    Alessi, Iside
    Colafati, Giovanna Stefania
    Carai, Andrea
    Diomedi-Camassei, Francesca
    De Billy, Emmanuel
    Agolini, Emanuele
    Mastronuzzi, Angela
    Locatelli, Franco
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [2] Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma
    Rose, A. A. N.
    DRUGS OF TODAY, 2019, 55 (04) : 247 - 264
  • [3] Vemurafenib in Melanoma with BRAF V600E Mutation
    Morita, Hiroyuki
    Nagai, Ryozo
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15): : 1448 - 1448
  • [4] Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
    Ito, Takamichi
    Kaku-Ito, Yumiko
    Murata, Maho
    Furue, Kazuhisa
    Shen, Che-Hung
    Oda, Yoshinao
    Furue, Masutaka
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [5] Dabrafenib in advanced melanoma with BRAF V600E mutation
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (02): : 48 - 49
  • [6] Vemurafenib in Melanoma with BRAF V600E Mutation REPLY
    Chapman, Paul B.
    Hauschild, Axel
    McArthur, Grant A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15): : 1450 - 1450
  • [7] BRAF V600E and V600K in Melanoma: Clinicopathologic Correlation
    Purgina, B. M.
    Jelic, T.
    Chiosea, S. I.
    LABORATORY INVESTIGATION, 2012, 92 : 131A - 131A
  • [8] BRAF V600E and V600K in Melanoma: Clinicopathologic Correlation
    Purgina, B. M.
    Jelic, T.
    Chiosea, S. I.
    MODERN PATHOLOGY, 2012, 25 : 131A - 131A
  • [9] Dataset: Impact of β-Galactosylceramidase Overexpression on the Protein Profile of Braf(V600E) Mutated Melanoma Cells
    Capoferri, Davide
    Chiodelli, Paola
    Calza, Stefano
    Manfredi, Marcello
    Presta, Marco
    Damasevicius, Robertas
    DATA, 2023, 8 (12)
  • [10] BRAF Wild-Type Melanoma in Situ Arising In a BRAF V600E Mutant Dysplastic Nevus
    Tan, Jean-Marie
    Lin, Lynlee L.
    Lambie, Duncan
    Flewell-Smith, Ross
    Jagirdar, Kasturee
    Schaider, Helmut
    Sturm, Richard A.
    Prow, Tarl W.
    Soyer, H. Peter
    JAMA DERMATOLOGY, 2015, 151 (04) : 417 - 421